AstraZeneca-Alexion US clearance shows big pharma deals can still avoid deep probes
The clearance of AstraZeneca’s acquisition of Alexion by the Federal Trade Commission shows that large pharmaceutical deals can still escape lengthy scrutiny during the Biden administration despite promises for tougher enforcement....To view the full article, register now.
Already a subscriber? Click here to view full article